Annual Reports

For 100 years, CSL has earned a reputation as a passionate yet responsible organization that is driven to care for patients and deliver on its commitments. Today, our future has never looked brighter. We expect that emerging new innovations and support programs can provide unprecedented opportunities to improve patient wellbeing unlike any other time in history.

View archived annual reports

2018/19 Annual Report

CSL’s reported net profit after tax was US$1,919 million for the year ended 30 June 2019. On a constant currency basis, net profit after tax was US$2,015 million. Total ordinary dividends for the year were US$1.85 per share. Read our 2018/19 Annual Report
2019 Annual General Meeting

Key Business Highlights

CSL continues to deliver on its strategy, with an 11%^# increase in total revenue. The strength of our results reflects the execution of our strategic plan and patient-focussed workforce.


	GROWTH Maximize portfolio value & deliver new product launches A strong year for CSL with revenue up 11%¹ and reported net profit after tax of $1,919 million, up 17% at constant currency¹. Continued strong growth in our core immunoglobulin and albumin therapies, with PRIVIGEN® sales up 23%¹, HIZENTRA® sales up 22%¹ and Albumin sales up 15% ¹. HAEGARDA®, our therapy for patients with Hereditary Angioedema (HAE) and IDELVION®, our therapy for Haemophilia B patients, have been transformational products with sales growth reflecting this - HAEGARDA® sales grew by 61%1 and IDELVION® sales are up 40%¹.
	EFFICIENCY Be the most efficient, highest quality plasma player Opened 30 new plasma collection centres in the United States (US). Rollout of enterprise resource planning systems continues successfully. Major capital projects at all manufacturing sites progressing to support future demand. Underwent 440 regulatory inspections of our manufacturing facilities* with no impact to licences or operations.
	INFLUENZA Delivery on influenza strategy Seqirus is delivering on strategy with strong profit growth. Total sales up 19%.¹ FLUAD®, indicated for active immunisation against influenza in the elderly 65 years and older, sales more than doubled. Compelling real world effectiveness data for FLUCELVAX®, cell culture derived influenza vaccine.
	INNOVATION Pursue new opportunities to diversify portfolio and enhance growth New Bio21 research facility opens in premier medical research hub in Melbourne, Australia. Good progress with early portfolio and in later stage projects with patients in more than 44 countries enrolled in CSL112 phase III for cardiovascular disease and CSL312 (targeting Factor XIIa) phase II study in patients with HAE commenced. Achieved 24 product registrations or new indications in numerous countries.
	PEOPLE & CULTURE Create a culture that attracts, retains and develops the best talent Appointment of Chief Operating Officer and also an Executive Vice President and General Manager for Seqirus. Employee workforce up 13%, with 57% of our employee base female. Achieved 74% employee engagement score. Workplace safety improvement plans developed.
	SHARED VALUE Support responsible business practice and trust with our stakeholders US$8.4 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions. US$56 million in global community investment across our strategic areas of support.

^#Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to CSL’s Financial Statements for the Full Year ended 2018 (Directors’ Report).
¹Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. For further detail please refer to CSL’s Financial Statements for the Full Year ended June 2019 (Directors’ Report) of CSL’s 2018/19 Annual Report.
*Does not include Ruide.

Annual Report Archive

This archive features CSL Limited's Annual Reports between 2013 and 2019